ImmunoGen

ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q3 2024

ImmunoGen reports successful 2022, eyes growth opportunities in 2023

ImmunoGen's strong 2022 performance, strategic partnerships, and positive market feedback set the stage for continued growth. While facing challenges in expenses and revenue targets, the company is well-positioned to capitalize on upcoming milestones and revenue streams.

ImmunoGen reports robust Q1 revenue, eyes growth opportunities

ImmunoGen's Q1 2023 earnings call showcased strong revenue performance
ELAHERE's market uptake and physician feedback remain positive
Operational challenges include increased expenses and regulatory evolution
Opportunities lie in resistance mechanisms study and program expansions

ImmunoGen reports strong Q2 revenue, focuses on Elahere growth

ImmunoGen's Q2 performance showed revenue growth and strong cash position
Elahere's success in trials and sales presents growth opportunities
Challenges include managing expenses and competition in the market
Opportunities lie in R&D investments, market expansion, and guideline updates

ImmunoGen reports robust Q3 earnings, eyes global expansion opportunities

ImmunoGen's strong financial performance and ELAHERE's success highlight a promising quarter.
Challenges include late responses in data sets and understanding the FR alpha and CDH overlap.
Opportunities lie in providing future revenue guidance, expanding globally, and exploring new molecules.
Overall, ImmunoGen's focus on ELAHERE's growth and strategic initiatives position it well for the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ImmunoGen, Inc. engages in the research and development of antibody-based anticancer therapeutics in the United States. The company develops therapeutics for the treatment of cancer using its Targeted Antibody Payload (TAP) technology, which uses antibodies to deliver a potent cytotoxic agent. Its products include Trastuzumab-DM1, a Phase II clinical trial product for the treatment of metastatic breast cancer; IMGN901, a Phase I clinical trial product to treat hematological malignancies, including multiple myeloma, small-cell lung cancer, Merkel cell carcinoma, and other cancers of neuroendocrine origin; SAR3419, a Phase I clinical trial product for the treatment of B-cell hematological malignancies, including non-Hodgkin's lymphoma; and IMGN388 and BIIB015, which are in Phase I clinical trials for the treatment of solid tumors. The company's products also comprise BT-062, a Phase I clinical trial product targeting multiple myeloma; SAR566658, a preclinical trail product for the treatment of breast, ovarian, and other solid tumors; SAR650984, a preclinical trail product to treat hematological malignancies; and TAP and other compounds. It has licensing or collaboration agreements with sanofi-aventis; Genentech, Inc.; Biotest AG; Bayer HealthCare AG; Biogen Idec; Amgen, Inc.; Centocor, Inc.; Cytovance Biologics LLC; Laureate Pharma, Inc.; BioInvent International AB; Diosynth RTP, Inc.; and Societa Italiana Corticosteroidi S.r.l. ImmunoGen was founded in 1981 and is headquartered in Waltham, Massachusetts.

ImmunoGen (IMGN) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.24 per share a year ago.

ImmunoGen (IMGN) Reports Q2 Loss, Tops Revenue Estimates

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Departure of Anna Berkenblit, Chief Medical Officer.

ImmunoGen Announces Departure of Anna Berkenblit, Chief Medical Officer

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Reports Recent Progress and Second Quarter 2023 Financial Results.

ImmunoGen Reports Recent Progress and Second Quarter 2023 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will participate in a fireside chat at the upcoming Canaccord Genuity 43rd Annual Growth Conference in Boston, MA. The presentation is scheduled for August 10, 2023 at 10:00 am ET. A webcast of the presentation will be accessible through the “Investors and Media” section of the Company's website, www.imm.

ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Canaccord Genuity 43rd Annual Growth Conference

ImmunoGen (IMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ImmunoGen (IMGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Multi-Target License and Option Agreement with ImmunoBiochem to Develop Next-Generation Antibody-Drug Conjugates.

ImmunoGen Announces Multi-Target License and Option Agreement with ImmunoBiochem to Develop Next-Generation Antibody-Drug Conjugates

ELAHERE only has accelerated approval from the FDA; the confirmatory trial was positive. The company's lead product seems to have nowhere near the insurance coverage that management claims. However, the antibody-drug conjugate is better than chemotherapy, and will likely dominate its sizable niche market.

ImmunoGen's ELAHERE Has Likely Blockbuster Potential

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Monday, July 31, 2023 to discuss its second quarter 2023 operating results. Management will also provide a brief update on the business. CONFERENCE CALL INFORMATION To access the live call by phone, please register here. A dial-in and unique PIN will be provi.

ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2023 Operating Results

ImmunoGen (IMGN) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, IMGN broke through the 20-day moving average, which suggests a short-term bullish trend.

ImmunoGen (IMGN) Crossed Above the 20-Day Moving Average: What That Means for Investors

ImmunoGen's Q1 2023 revenue increased to $49.9 million, primarily due to sales of Elahere and an upfront fee from Vertex Pharmaceuticals. The company plans to close a $325 million public offering. The MIRASOL trial confirmed Elahere's potential as a transformative therapy for platinum-resistant ovarian cancer, with significant improvements in both progression-free survival and overall survival compared to chemotherapy. Despite potential risks such as regulatory hurdles, market penetration rates, and competition, ImmunoGen remains a "Buy" due to its strong clinical efficacy data in ovarian cancer.

ImmunoGen: Comprehensive MIRASOL Data Reinforces Elahere's Potential

BioMarin Pharmaceutical

Navigating the choppy waters in the biotech sphere can be daunting, which makes it a challenge to hunt for the top high return biotech stocks. The journey to market approval, encumbered by volatile clinical trials and regulatory roadblocks, can be an uphill battle.

3 Biotech Stocks to Make Your ‘Get Rich' Dreams Come True

C3.ai

IonQ

Opera Ltd - ADR

Riot Blockchain

The scorching 2023 S&P 500 market rally has been red hot.  As a result, we're seeing quite a few sizzling market outperformers.

5 Sizzling Stocks That Are Outperformers in the Market This Year

ImmunoGen Inc. NASDAQ: IMGN is a commercial-stage biotechnology company leading in antibody-drug conjugates (ADC). ADCs are like heat-seeking missiles that target and selectively deliver cancer-killing toxins to tumor cells while leaving healthy cells alone using antibodies that bind to antigens found on targeted cancer cells.

ImmunoGen Stock Continues to Defy Gravity on Phase 2 Trials

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced updated data from an interim analysis of the Phase 2 CADENZA trial of pivekimab sunirine (pivekimab) in patients with frontline and relapsed/refractory (R/R) blastic plasmacytoid dendritic cell neoplasm (BPDCN). The data will be presented in an oral session on Sunday, June 11 at the European Hematology Association (EHA) 2.

ImmunoGen Presents Updated Findings from CADENZA Trial of Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm at EHA 2023 Congress

Day One Biopharmaceuticals

Evaxion Biotech A/S

G1 Therapeutics

Shares of several cancer drug firms surged on Monday after the companies reported positive clinical trial data from their therapies at an ongoing industry conference in Chicago.

Cancer drugmakers rise as industry meet fuels investor interest

ImmunoGen and Day One unveiled promising cancer treatment updates over the weekend, leading IMGN stock and DAWN stock to soar Monday.

ImmunoGen, Day One Surge On Cancer Drug Updates, But Arcus Crashes

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Jefferies Healthcare Conference.

ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Jefferies Healthcare Conference

ImmunoGen's (IMGN) recently launched drug, Elahere, is expected to generate incremental revenues for the company and boost its top-line growth in the next few years.

Here's Why You Should Add ImmunoGen (IMGN) to Your Portfolio Now

Biogen

Vertex Pharmaceuticals

The biotechnology (or biotech) sector is a crystal-clear illustration of risk and reward. Many biotech companies work on drugs and therapeutics for some of the most pernicious conditions affecting our society and healthcare system.

3 Biotech Stocks That Are Revolutionizing Healthcare in 2023

American Express

bluebird bio

Discover

Goldman Sachs

Eli Lilly

SoFi Technologies

The Regional Bank Fiasco is a classic “Baby with the Bathwater” scenario. Rising rates are great for Insurance companies and “hidden banks”.

Tech Titans Aren't The Only Game In Town, Consider Biotech And, Yes, Financials

ImmunoGen (IMGN) shares surge exponentially in the past month owing to the positive data on the expansion study of Elahere for ovarian cancer. An encouraging initial sales uptake of its first marketed product, Elahere, also contribute to the surge.

ImmunoGen (IMGN) Stock Surges 230% in a Month: Here's Why

ImmunoGen, Inc. lead drug (Elahere) recently gained accelerated approval to treat patients afflicted by platinum-resistant ovarian cancers with the high FRA expression. The Q1 earnings report showed that the blockbuster prospect (Elahere) is gaining stronger traction than what the market anticipated.

ImmunoGen: Making A Successful Comeback

After reaching an important support level, ImmunoGen, Inc. (IMGN) could be a good stock pick from a technical perspective. IMGN recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.

Should You Buy ImmunoGen (IMGN) After Golden Cross?

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the closing of its previously announced underwritten public offering of 29,900,000 shares of its common stock, which reflects the exercise in full by the underwriters of their option to purchase up to 3,900,000 additional shares of common stock. The shares of common stock were sold at a price of $12.50 per share before u.

ImmunoGen Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

ImmunoGen, Inc. ELAHERE succeeds in phase 3 confirmatory MIRASOL trial; all endpoints achieved with statistical significance when FRa-high positive platinum-resistant ovarian cancer patients received ELAHERE. Submission of BLA of ELAHERE to the FDA to convert Accelerated Approval to a Full approval is expected in the 2nd half of 2023.

News for ImmunoGen Stock (IMGN)